RECRUITING

Trifecta-Kidney cfDNA-MMDx Study

Talk to us

Conditions

Kidney Transplant Rejectiondonor derived cell-free DNAbloodkidney biopsy

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

Official Title

Trifecta-Kidney cfDNA-MMDx Study: Comparing the DD-cfDNA Test to MMDx Microarray Test, Central HLA Antibody Test, and Histology.

Quick Facts

Study Start:2019-12-01
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04239703

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.
  1. * Patients will be excluded from the study if they decline participation or are unable to give informed consent or multiple organ recipients.

Contacts and Locations

Study Contact

Konrad S Famulski, PhD
CONTACT
1 780 492 1725
konrad@ualberta.ca
Robert Polakowski, PhD
CONTACT
1 780 492 5091
polakows@ualberta.ca

Principal Investigator

Philip F Halloran, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Alberta

Study Locations (Sites)

Tampa General Hospital
Tampa, Florida, 33606
United States
University of Maryland School of Medicine
Baltimore, Maryland, 21201
United States
The Johns Hopkins University, School of Medicine
Baltimore, Maryland, 21205
United States
Detroit Medical Center, Harper University Hospital of Wayne State University
Detroit, Michigan, 48201
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
Barnes-Jewish Hospital, Washington University at St. Louis
Saint Louis, Missouri, 63110
United States
University Hospitals Cleveland Medical Ctr.
Cleveland, Ohio, 44106-5048
United States
Cleveland Clinic
Cleveland, Ohio, 44195
United States
Intermountain Transplant Services
Murray, Utah, 84107
United States
Virginia Commonwealth University Medical Center
Richmond, Virginia, 23298
United States
Division of Nephrology & UW Organ Transplant Center University of Washington
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: University of Alberta

  • Philip F Halloran, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Alberta

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-12-01
Study Completion Date2026-12

Study Record Updates

Study Start Date2019-12-01
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • donor derived cell-free DNA
  • blood
  • kidney biopsy

Additional Relevant MeSH Terms

  • Kidney Transplant Rejection